Cart
sales@molnova.com
Home - Products - Microbiology/Virology - HIV - Ibalizumab

Ibalizumab

CAS No. 680188-33-4

Ibalizumab( —— )

Catalog No. M36665 CAS No. 680188-33-4

Ibalizumab(TMB-355) is a humanized IgG4 monoclonal antibody that acts as a CD4 receptor inhibitor, blocking the entry of HIV-1 into cells by binding to the CD4 receptor.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 1881 In Stock
10MG 2537 In Stock
25MG 3762 In Stock
50MG 4976 In Stock
100MG 6715 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock
Get Quotation Bulk Inquiry Add to Cart

Biological Information

  • Product Name
    Ibalizumab
  • Note
    Research use only, not for human use.
  • Brief Description
    Ibalizumab(TMB-355) is a humanized IgG4 monoclonal antibody that acts as a CD4 receptor inhibitor, blocking the entry of HIV-1 into cells by binding to the CD4 receptor.
  • Description
    Ibalizumab (TMB-355) is a humanised IgG4 monoclonal antibody that prevents HIV cell entry by binding to CD4 receptor. Ibalizumab has the potential for HIV-1 infection research.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Microbiology/Virology
  • Target
    HIV
  • Recptor
    HIV Protease
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    680188-33-4
  • Formula Weight
  • Molecular Formula
    ——
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ——
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Anthony Markham. Ibalizumab: First Global Approval. Drugs. 2018 May;78(7):781-785. ?
Calculator

Molecular Weight Calculator

Dilution Calculator

Molarity Calculator

molnova catalog
related products

  • BMS-538203

    A chemical intermidate of BMS-626529, a HIV-1 attachment inhibitor that targets gp120,

  • Punicalin

    Punicalin exerts anti-inflammatory antioxidative and anti-hepatotoxic activities it shows inhibitory activity on HIV-1 reverse transcriptase in a dose-dependent manner with an IC50 of 0.11 microg/ml (0.14 microM).

  • BNM-III-170

    BNM-III-170 is a small-molecule CD4-mimetic compound that enhances vaccine efficacy against HIV-1 challenge in vivo.

Sign In Join Free